Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Catalog No. ABIN6953046

The Human Monoclonal anti-SARS-CoV-2 Spike S1 antibody has been validated for ELISA, Crys, SPR and Neut. It is suitable to detect SARS-CoV-2 Spike S1 in samples from SARS Coronavirus-2 (SARS-CoV-2) and SARS Coronavirus (SARS-CoV).

Quick Overview for Recombinant SARS-CoV-2 Spike S1 antibody (RBD) (ABIN6953046)

Target: SARS-CoV-2 Spike S1

Antibody Type: Recombinant Antibody

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike S1 antibody is un-conjugated

Application: ELISA, Crystallization (Crys), Surface Plasmon Resonance (SPR), Neutralization (Neut)

Clone: CR3022

Product Details anti-SARS-CoV-2 Spike S1 Antibody

Binding Specificity: RBD

Purpose: Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.

Specificity:

The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

Cross-Reactivity (Details): The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

Characteristics: The original monoclonal antibody (CR3022) was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Several anti-SARS-CoV-2 Spike Protein (Subunit S1) antibodies based on clone CR3022 are available:
Human IgG1, IgG2, IgG3, IgA and IgM for use in neutralization assays and as serological controls

• ABIN6952546 - Human IgG1
• ABIN6953046 - Human IgG2
• ABIN6953052 - Human IgG3
• ABIN6953047 - Human IgA
• ABIN6953042 - Human IgM

Rabbit IgG, mouse IgG2b and mouse IgM for detection applications, co-labelling studies and animal model research

• ABIN6952547 - Rabbit IgG
• ABIN6953044 - Mouse IgG2b
• ABIN6953043 - Mouse IgM

Human and mouse Fab and Fab2 formats with His-tags, for applications where antibody fragments are desirable and for site-specific functionalization

• ABIN6953048 - Human Fab fragment, His tag
• ABIN6953050 - Human F(ab)2 fragment, His tag
• ABIN6953049 - Mouse Fab fragment, His tag
• ABIN6953051 - Mouse F(ab)2 fragment, His tag

Human IgG1 and mouse IgG2b Fc-Mutant formats, which are aimed at discerning Fc-dependent and Fc-independent effector functions and facilitating research into the role of antibody-dependent enhancement (ADE)

• ABIN6953041 - Human IgG1, Fc-Mutant
• ABIN6953045 - Mouse IgG2b, Fc-Mutant

Purification: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Isotype: IgG2b

Application Details

Application Notes: This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 is available to assess its yet unknown role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).

Comment:

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Target Type: Viral Protein

Background: Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV

UniProt: P59594